These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 25311263)

  • 41. Improving fine needle aspiration to predict the tumor biological aggressiveness in pancreatic neuroendocrine tumors using Ki-67 proliferation index, phosphorylated histone H3 (PHH3), and BCL-2.
    Zhao CL; Dabiri B; Hanna I; Lee L; Xiaofei Z; Hossein-Zadeh Z; Cao W; Allendorf J; Rodriguez AP; Weng K; Turunbedu S; Boyd A; Gupta M
    Ann Diagn Pathol; 2023 Aug; 65():152149. PubMed ID: 37119647
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Solid non-functioning endocrine tumors of the pancreas: correlating computed tomography and pathology.
    Zamboni GA; Ambrosetti MC; Zivelonghi C; Lombardo F; Butturini G; Cingarlini S; Capelli P; Pozzi Mucelli R
    HPB (Oxford); 2017 Nov; 19(11):986-991. PubMed ID: 28784262
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of 18F-fluorodeoxyglucose PET in the study of neuroendocrine tumors.
    Panagiotidis E; Bomanji J
    PET Clin; 2014 Jan; 9(1):43-55. PubMed ID: 25029933
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Contrast-enhanced MDCT in patients with pancreatic neuroendocrine tumours: correlation with histological findings and diagnostic performance in differentiation between tumour grades.
    Belousova E; Karmazanovsky G; Kriger A; Kalinin D; Mannelli L; Glotov A; Karelskaya N; Paklina O; Kaldarov A
    Clin Radiol; 2017 Feb; 72(2):150-158. PubMed ID: 27890421
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 18F-FDG Uptake in Well-Differentiated Neuroendocrine Tumors Correlates with Both Ki-67 and VHL Pathway Inactivation.
    Bucau M; Laurent-Bellue A; Poté N; Hentic O; Cros J; Mikail N; Rebours V; Ruszniewski P; Lebtahi R; Couvelard A
    Neuroendocrinology; 2018; 106(3):274-282. PubMed ID: 28803235
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Usefulness of dual-phase 18F-FDG PET/CT for diagnosing small pancreatic tumors.
    Kawada N; Uehara H; Hosoki T; Takami M; Shiroeda H; Arisawa T; Tomita Y
    Pancreas; 2015 May; 44(4):655-9. PubMed ID: 25815646
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pretreatment [18F]-fluoro-2-deoxy-glucose positron emission tomography maximum standardized uptake value as predictor of distant metastasis in early-stage non-small cell lung cancer treated with definitive radiation therapy: rethinking the role of positron emission tomography in personalizing treatment based on risk status.
    Nair VJ; MacRae R; Sirisegaram A; Pantarotto JR
    Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):312-8. PubMed ID: 24411602
    [TBL] [Abstract][Full Text] [Related]  

  • 48. F18-FDG PET-CT analyses of small peripheral adenocarcinoma of the lung.
    Takahashi Y; Takashima S; Watanabe S; Tomita Y; Hakucho T; Miyake C; Morimoto D; Hosoki T; Nakanishi K; Higashiyama M
    Acta Radiol; 2013 Mar; 54(2):164-8. PubMed ID: 23138022
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Grade 3 Pancreatic Neuroendocrine Tumors on MDCT: Establishing a Diagnostic Model and Comparing Survival Against Pancreatic Ductal Adenocarcinoma.
    Chen HY; Zhang XY; Deng XY; Ge YL; Tang YQ; Cui H; Yang B; Pan Y; Shi D; Yu RS
    AJR Am J Roentgenol; 2020 Aug; 215(2):390-397. PubMed ID: 32432906
    [No Abstract]   [Full Text] [Related]  

  • 50. Prospective evaluation of the clinical utility of 18-fluorodeoxyglucose PET CT scanning in patients with von hippel-lindau-associated pancreatic lesions.
    Sadowski SM; Weisbrod AB; Ellis R; Patel D; Alimchandani M; Quezado M; Millo C; Venzon DJ; Nilubol N; Linehan WM; Kebebew E
    J Am Coll Surg; 2014 May; 218(5):997-1003. PubMed ID: 24661849
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Is the combination of MR and CT findings useful in determining the tumor grade of pancreatic neuroendocrine tumors?
    Toshima F; Inoue D; Komori T; Yoshida K; Yoneda N; Minami T; Matsui O; Ikeda H; Gabata T
    Jpn J Radiol; 2017 May; 35(5):242-253. PubMed ID: 28258323
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dual-Tracer (68Ga-DOTATOC and 18F-FDG-)-PET/CT Scan and G1-G2 Nonfunctioning Pancreatic Neuroendocrine Tumors: A Single-Center Retrospective Evaluation of 124 Nonmetastatic Resected Cases.
    Paiella S; Landoni L; Tebaldi S; Zuffante M; Salgarello M; Cingarlini S; D'Onofrio M; Parisi A; Deiro G; Manfrin E; Bianchi B; Montagnini G; Crinò SF; Bassi C; Salvia R
    Neuroendocrinology; 2022; 112(2):143-152. PubMed ID: 33508821
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of SUV(max) obtained by 18F-FDG PET/CT in patients with a solitary pancreatic lesion: predicting malignant potential and proliferation.
    Hu SL; Yang ZY; Zhou ZR; Yu XJ; Ping B; Zhang YJ
    Nucl Med Commun; 2013 Jun; 34(6):533-9. PubMed ID: 23503000
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Increased fluorine-18 2-fluoro-2-deoxy-D-glucose (FDG) uptake in childhood CNS tumors is correlated with malignancy grade: a study with FDG positron emission tomography/magnetic resonance imaging coregistration and image fusion.
    Borgwardt L; Højgaard L; Carstensen H; Laursen H; Nowak M; Thomsen C; Schmiegelow K
    J Clin Oncol; 2005 May; 23(13):3030-7. PubMed ID: 15860860
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions.
    Lan XL; Zhang YX; Wu ZJ; Jia Q; Wei H; Gao ZR
    Clin Radiol; 2008 Jul; 63(7):756-64. PubMed ID: 18555033
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Diagnosis of pancreatic cancer using ¹⁸F-FDG PET/CT and CA19-9 with SUVmax association to clinical characteristics.
    Sun Y; Duan Q; Wang S; Zeng Y; Wu R
    J BUON; 2015; 20(2):452-9. PubMed ID: 26011335
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The feasibility of 18F-fluorodeoxyglucose-positron emission tomography uptake as a prognostic factor for paranasal sinus malignancy.
    Seol JH; Kim J; Lee JD; Lee JG; Yoon JH; Kim CH
    Am J Rhinol Allergy; 2013; 27(2):118-22. PubMed ID: 23562200
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG.
    Kayani I; Bomanji JB; Groves A; Conway G; Gacinovic S; Win T; Dickson J; Caplin M; Ell PJ
    Cancer; 2008 Jun; 112(11):2447-55. PubMed ID: 18383518
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma.
    Swisher SG; Erasmus J; Maish M; Correa AM; Macapinlac H; Ajani JA; Cox JD; Komaki RR; Hong D; Lee HK; Putnam JB; Rice DC; Smythe WR; Thai L; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
    Cancer; 2004 Oct; 101(8):1776-85. PubMed ID: 15386332
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Detection of pancreatic neuroendocrine tumors (PNET) using semi-quantitative [68Ga]DOTATOC PET in combination with multiphase contrast-enhanced CT.
    Froeling V; Röttgen R; Collettini F; Rothe J; Hamm B; Brenner W; Schreiter N
    Q J Nucl Med Mol Imaging; 2014 Sep; 58(3):310-8. PubMed ID: 25265251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.